Current therapies for non-Hodgkin lymphoma commonly include CD20 mAb to deplete
tumor cells. However, the response is not durable in a substantial proportion of patients …

Anti-CD20 antibody immunotherapy effectively treats non-Hodgkin's lymphoma and
autoimmune disease. However, the cellular and molecular pathways for B cell depletion …

Despite the demonstrated clinical efficacy of CD20 monoclonal antibody (mAb) for
lymphoma therapy, the in vivo mechanisms of tumor depletion remain controversial and …

Although anti-CD20 immunotherapy effectively treats human lymphoma and autoimmune
disease, the in vivo effect of immunotherapy on tissue B cells and their subsets is generally …

Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy arising from germinal
center or post-germinal center B-cells that retain many of the properties of normal B-cells …

Malignant B cells responding to external stimuli are likely to gain a growth advantage in vivo.
These cells may therefore maintain surface CD19 expression to amplify transmembrane …

Currently, the lineage-specific cell-surface molecules CD19 and CD20 present on many B-
cell malignancies are targets for both antibody-and cell-based therapies. Coupling these two …

Purpose: Anti-CD20 monoclonal antibodies (mAb) are an important immunotherapy for B-
cell lymphoma, and provide evidence that the immune system may be harnessed as an …

B cell activation is regulated by a variety of signals. CD19 positively regulates B cell
activation, augmenting signals delivered through the BCR complex. In contrast, CD32b …

Activation of natural killer (NK) cells in the presence of interleukin-12 (IL-12) augments the
capacity of these effector cells to recognize B7-1–and B7-2–expressing target cells. These …